Johns Hopkins ABX Guide
Mefloquine
INDICATIONS
FDA
FDA
- Treatment of mild to moderate acute malaria (P. falciparum and P. vivax) caused by chloroquine-resistant, chloroquine-susceptible and multiple-drug-resistant (including sulfadoxine and pyrimethamine-resistant) strains
- Malaria (P. falciparum and P. vivax) prophylaxis including prophylaxis of chloroquine-resistant strains of P. falciparum.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: October 10, 2021
Citation
Avdic, Edina. "Mefloquine." Johns Hopkins ABX Guide, The Johns Hopkins University, 2021. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540338/all/Mefloquine.
Avdic E. Mefloquine. Johns Hopkins ABX Guide. The Johns Hopkins University; 2021. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540338/all/Mefloquine. Accessed December 18, 2024.
Avdic, E. (2021). Mefloquine. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540338/all/Mefloquine
Avdic E. Mefloquine [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2021. [cited 2024 December 18]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540338/all/Mefloquine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Mefloquine
ID - 540338
A1 - Avdic,Edina,Pharm.D.
Y1 - 2021/10/10/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540338/all/Mefloquine
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
